NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Jaguar Health, Inc. (JAGX) Stock Analysis

Jaguar Health, Inc. (JAGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

JAGX

$2.28

−$0.35 (−13.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JAGX with… →

JAGX Key Statistics

As of Oct 21, 2026
Trading
Open
$2.58
Previous Close
$2.63
Day's Range
2.25–2.66
52-Week Range
2.25–1,118.25
Volume
491.87K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.11
Valuation
Market Cap
$4.44M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.16
Financials (FY)
Revenue (FY)
$11.51M−1.52%
Net Income (FY)
−$53.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
−130.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.95M
1-Year Return
−99.78%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
2.09M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, JAGX closed at $2.28, −99.78% over 1 year.

Jaguar Health, Inc. (JAGX) has a market capitalization of $4.44M.

In fiscal 2025, JAGX reported revenue of $11.51M.

JAGX Stock Return by Calendar Year

Jaguar Health, Inc. (JAGX) return since Jan 2025: what $10,000 became

1 year
$10,000 $22
−99.78%
Since Jan 2025
$10,000 $2
−99.98%

If you had invested $10,000 in Jaguar Health, Inc. (JAGX) at the close on January 13, 2025, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −99.22% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−99.53%
2025−95.98%

As of October 21, 2026.

JAGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.51M−$53.43M−464.2%
2024$11.69M−$38.49M−329.3%
2023$9.76M−$41.30M−423.1%
2022$11.96M−$47.45M−396.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.51M$7.74M−$45.11M−$53.43M−464.2%
2024$11.69M$9.73M−$30.83M−$38.49M−329.3%
2023$9.76M$7.72M−$33.92M−$41.30M−423.1%
2022$11.96M$9.94M−$34.42M−$47.45M−396.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JAGX Valuation vs Biotechnology Median

Median of 608 stocks
MetricJAGXBiotechnology medianvs median
P/S ratio0.1613.300.0x the median
Profit margin−130.85%−38.31%92.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Jaguar Health, Inc. (JAGX) is capitalised at $4.44M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 47 employees.

Over the past 52 weeks the price has ranged from $2.25 to $1,118.25. JAGX last closed at $2.28 on October 21, 2026. That is −$0.35 (−13.31%) against the previous close. The latest close sits 1.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.51M. Against the prior fiscal year total of $11.69M, that is a change of −1.52%. The same year closed with a net loss of $53.43M. Profit margin runs at −130.85%. That is 92.5 percentage points below the Biotechnology median of −38.31%.

Across the 4 fiscal years on file, revenue moves from $11.96M in 2022 to $11.51M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.16. On price-to-sales that is 0 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −99.78%. The stored price history starts on January 13, 2025, and the total return since then is −99.98%. Beta against the wider market is reported at −0.11. Daily returns over the trailing 1 year annualize to a volatility of 1,210.5%.

Growth & Income

The record shows no dividend for JAGX.

2026 is still running; the total return is −99.53% year to date. The record holds one complete calendar year, 2025, which returned −95.98%.

Peer Comparison

Jaguar Health, Inc. (JAGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jaguar Health, Inc. JAGX $4.44M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Jaguar Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Visit website →